Drug Trial Radar · NCT05733351
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Aug 3, 2023
Primary completion
Jun 12, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); Xencor, Inc.
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety and effectiveness of vudalimab (XmAb20717) in combination with standard of care treatment abiraterone, enzalutamide, or abiraterone plus docetaxel in treating patients with castration sensitive prostate cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding vudalimab to standard of care treatments may be effective in treating metastatic castration sensitive prostate cancer.
Conditions
- Castration-Sensitive Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
AbirateroneDrug
Given PO
Biospecimen CollectionProcedure
Undergo blood and stool sample collection
Bone ScanProcedure
Undergo bone scan
Computed TomographyProcedure
Undergo CT
DocetaxelDrug
Given IV
EnzalutamideDrug
Given PO
FDG-Positron Emission TomographyProcedure
Undergo FDG PET
Magnetic Resonance ImagingProcedure
Undergo MRI
PSMA PET ScanProcedure
Undergo PSMA PET
VudalimabDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Up to 70 days post treatment
- Radiographic Progression-Free SurvivalTime frame: Up to 3 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.